On May 1, 2018 Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, reported the appointment of David Taylor, M.D., as Chief Medical Officer. Dr. Taylor brings over 35 years of extensive experience in medical research, drug and vaccine development and clinical trial management for government organizations, non-profits, academia and both private and public healthcare companies (Press release, Vaxart, MAY 1, 2018, View Source [SID1234525899]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Strengthening our leadership team with the appointment of David is an important milestone for Vaxart as we continue to advance our oral vaccine platform. Dr. Taylor is a drug discovery and development veteran with deep industry knowledge developing recombinant and enteric vaccines, with expertise in the design, execution and analysis of norovirus and influenza vaccine clinical trials," said Wouter Latour, chief executive officer of Vaxart. "We are pleased to welcome David and are confident his guidance will prove invaluable as we move our vaccine programs further in the clinic."
Prior to joining Vaxart, Dr. Taylor served as a senior medical officer of the drug and vaccine development global programs at PATH, where he developed clinical trial designs and executed studies for seasonal and universal flu vaccines and enteric vaccines. Earlier, he was senior medical director of vaccines at Takeda Vaccines, developing clinical trial plans for norovirus and dengue vaccines. Previously, Dr. Taylor served as chief medical officer at VaxInnate Corporation, where he focused on the development of recombinant vaccines for influenza and other infectious diseases, and chief medical officer and vice president of medical and safety at Salix Pharmaceuticals, where he developed Rifaximin (Xifaxan) for the treatment of traveller’s diarrhea and headed medical affairs and pharmacovigilance.
Before Salix, he was a research professor for the Department of International Health at Johns Hopkins Bloomberg School of Public Health. Dr. Taylor began his career as an epidemic intelligence service officer in the Enteric Disease Branch at the Centers for Disease Control and Prevention (CDC) and served 22 years in various capacities at research institutes in the United States Army including founder and chief of the Department of Clinical Trials and acting director for the Division of Communicable Diseases and Immunology at the Walter Reed Army Institute of Research.
Dr. Taylor earned his MSc. in Medical Parasitology from the London School of Hygiene and Tropical Medicine, M.D. from Harvard Medical School, D.M.S. from Dartmouth Medical School and B.S. in Biology from Kenyon College.
About Vaxart